The knowledge-driven MARRVEL AI-based model (AIM) to identify Mendelian illnesses.
TG Therapeutics signs $645M deal to kick-start international launch of MS antibody
TG Therapeutics is looking to expand access to its CD20 antibody Briumvi outside North America and has announced a partnership with the European pharma company